SecurityGLOW / Glowpoint, Inc. (379887201)
PRESIDENT AND CEOHolst Peter
IndustryTelephone Communications, Except Radiotelephone
Institutional Owners17
Institutional Shares1,215,130 - 2.54%
Common Shares Outstanding47,908,000 shares (as of 2018-06-30)
Institutional Value$ 248,000 USD

Institutional Stock Ownership and Shareholders

Glowpoint, Inc. (AMEX:GLOW) has 17 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 1,215,130 shares. Largest shareholders include Geode Capital Management, Llc, Acadian Asset Management Llc, Panagora Asset Management Inc, Renaissance Technologies LLC, Cetera Advisors LLC, Vanguard Group Inc, UBS Group AG, Goldman Sachs Group Inc, Citadel Advisors Llc, and Creative Planning.
Glowpoint, Inc. (AMEX:GLOW) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-08-14 13F-HR PANAGORA ASSET MANAGEMENT INC 231,785 182,927 -21.08 51 37 -27.45
2018-08-13 13F-HR Stratos Wealth Partners, LTD. 4,500 0 -100.00 1 0 -100.00
2018-08-14 13F-HR GOLDMAN SACHS GROUP INC 29,811 29,811 0.00 7 6 -14.29
2018-08-14 13F-HR BARCLAYS PLC 1 0 -100.00 0 0
2018-07-24 13F-HR ACADIAN ASSET MANAGEMENT LLC 101,384 202,221 99.46 23 41 78.26
2018-08-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 51,095 17,310 -66.12 11 4 -63.64
2018-08-13 13F-HR Marino, Stram & Associates Llc 292 292 0.00 0 0
2018-08-14 13F-HR UBS Group AG 54,280 38,069 -29.87 12 7 -41.67
2017-02-10 13F-HR BlackRock Fund Advisors 3,105 4,185 34.78 1 1 0.00
2018-08-09 13F-HR BlackRock Inc. 7,855 8,567 9.06 2 2 0.00
2018-08-14 13F-HR TWO SIGMA SECURITIES, LLC 10,173 0 -100.00 2 0 -100.00
2018-08-14 13F-HR STATE STREET CORP 13,300 13,300 0.00 2 2 0.00
2018-07-20 13F-HR Creative Planning 25,000 5
2018-08-14 13F-HR VANGUARD GROUP INC 89,200 89,200 0.00 20 18 -10.00
2018-08-13 13F-HR HONKAMP KRUEGER FINANCIAL SERVICES INC /ADV 82 0 -100.00 0 0
2018-08-10 13F-HR NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO 3,000 3,000 0.00 1 1 0.00
2018-08-14 13F-HR Cetera Advisors LLC 94,020 94,020 0.00 21 19 -9.52
2018-07-20 13F-HR Steward Partners Investment Advisory, Llc 3,000 0 -100.00 0 0
2018-07-30 13F-HR/A Virtu Financial LLC 64,593 0 -100.00 14 0 -100.00
2018-08-14 13F-HR MORGAN STANLEY 0 25 0 0
2018-08-14 13F-HR GEODE CAPITAL MANAGEMENT, LLC 340,724 340,724 0.00 75 69 -8.00
2018-08-14 13F-HR ROYAL BANK OF CANADA 14 0 -100.00 0 0
2018-08-13 13F-HR Renaissance Technologies LLC 140,000 31
2018-08-14 13F-HR/A CITADEL ADVISORS LLC 34,215 26,479 -22.61 8 5 -37.50

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 379887201